MiniMed announces U.S. FDA clearance of MiniMed Flex

MiniMed (MMED) announced U.S. Food and Drug Administration, FDA, clearance of MiniMed Flex, a next-generation discreet, smartphone-controlled insulin pump designed to fit seamlessly into everyday life. “At MiniMed, our Mission is to make every day a better day for people with diabetes,” said Que Dallara, chief executive officer of MiniMed. “MiniMed Flex(TM) embodies that promise. It’s designed to work quietly and reliably in the background – advanced automation wrapped in a compact, smartphone-controlled pump. The result is technology that lets people spend less time managing diabetes and more time living their lives. Securing FDA clearance for our first product as a standalone, public company – just one week after our IPO – marks a major milestone and underscores our commitment to delivering the breakthrough innovation our customers deserve.”